Palbociclib + aromatase inhibitor

DRUG3 trials

Sponsors

Chinese Academy of Medical Sciences, Pfizer

Conditions

Hormone Receptor Positive Advanced Breast CancerMetastatic Breast Cancer

Unknown Phase

Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC

Chinese Academy of Medical SciencesHormone Receptor Positive Advanced Breast Cancer

Start: 2021-09-01End: 2022-09-01Target: 600Updated: 2022-04-29

Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone

CompletedNCT05012644

PfizerMetastatic Breast Cancer

Start: 2021-07-16End: 2021-12-09Updated: 2024-10-08

European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies

CompletedNCT05043506

PfizerMetastatic Breast Cancer

Start: 2022-02-08End: 2023-11-02Updated: 2026-06-30

Related Papers

Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer.

2023-07-105 citations

Comparative effectiveness of palbociclib plus aromatase inhibitor versus fulvestrant alone as initial endocrine therapy for HR+/HER2- advanced breast cancer in Chinese clinical practice: A real-world study.

Journal of Clinical Oncology2023-06-011 citations